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Abstract
Increased abundance of the prostate-specific membrane antigen (PSMA) on prostate epithelium is 
a hallmark of advanced metastatic prostate cancer (PCa) and correlates negatively with prognosis. 
However, direct evidence that PSMA functionally contributes to PCa progression remains elusive. 
We generated mice bearing PSMA-positive or PSMA-negative PCa by crossing PSMA-deficient 
mice with transgenic PCa (TRAMP) models, enabling direct assessment of PCa incidence and 
progression in the presence or absence of PSMA. Compared with PSMA-positive tumors, PSMA-
negative tumors were smaller, lower-grade, and more apoptotic with fewer blood vessels, 
consistent with the recognized proangiogenic function of PSMA. Relative to PSMA-positive 
tumors, tumors lacking PSMA had less than half the abundance of type 1 insulin-like growth 
factor receptor (IGF-1R), less activity in the survival pathway mediated by PI3K-AKT signaling, 
and more activity in the proliferative pathway mediated by MAPK-ERK1/2 signaling. 
Biochemically, PSMA interacted with the scaffolding protein RACK1, disrupting signaling 
between the β1 integrin and IGF-1R complex to the MAPK pathway, enabling activation of the 
AKT pathway instead. Manipulation of PSMA abundance in PCa cell lines recapitulated this 
signaling pathway switch. Analysis of published databases indicated that IGF-1R abundance, cell 
proliferation, and expression of transcripts for antiapoptotic markers positively correlated with 
PSMA abundance in patients, suggesting that this switch may be relevant to human PCa. Our 
findings suggest that increase in PSMA in prostate tumors contributes to progression by altering 
normal signal transduction pathways to drive PCa progression and that enhanced signaling through 
the IGF-1R/β1 integrin axis may occur in other tumors.
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INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed cancer in men in the United States 
and the second leading cause of cancer deaths in American men over 50 [after lung cancer 
(1)]. Although the precise cause of PCa remains unknown, clinical and experimental 
observations suggest that hormonal, genetic, and environmental factors may each play a role. 
It is well established that androgens play a crucial role in PCa development. In most of the 
early cases, PCa can be effectively treated by either surgery or targeted pharmacological 
manipulation of the androgen receptor (AR) and its target genes (2). Unfortunately, once 
metastatic disease develops, this therapy is no longer effective, in part related to the loss or 
mutation of AR in late-stage PCa, suggesting an activation or shift to alternate prosurvival 
cancer signaling pathways (3). Although the relationship between these signaling pathways 
most likely varies within different tumors, elucidation of the global molecular mechanisms 
responsible for this prosurvival switch is necessary to improve treatment strategies for 
patients with advanced-stage PCa.
One common mechanism promoting the malignant cell behavior involves changes in the 
activation status of receptor tyrosine kinases (RTKs). The type 1 insulin-like growth factor 
receptor (IGF-1R) has often been implicated in cancer progression (4, 5), and increased 
abundance of IGF-1R have been observed in most primary and metastatic prostate tumors 
(6). Evidence suggests that increased and sustained IGF-1R signaling underlies persistent 
PCa survival and growth as tumors progress to androgen independence (7). However, results 
from recent clinical trials targeting the IGF-1R pathway have been disappointing (8), 
suggesting that a more complex mechanism promotes malignant cell behavior. Alternatively, 
cross-talk between critical signal transduction pathways and aberrant activation of distinct 
pathways have both been implicated in cancer promotion (9), typified by the cross-talk 
between the IGF-1R and the β integrin signaling pathways, which has been implicated in 
breast cancer (10–21) and PCa (22–26), neuroblastoma (27, 28), and multiple myeloma (29), 
among others (30). Identification of the shared and unique participants of these pathways 
and their contribution to disease progression are necessary to improve therapeutic strategies 
for cancers of numerous etiologies.
PSMA is a 750–amino acid type II transmembrane peptidase enzyme that is encoded by the 
folate hydrolase 1 (FOLH1) gene. Although PSMA is also known as glutamate 
carboxypeptidase II, N-acetyl-L-aspartyl-L-glutamate peptidase I, and N-
acetylaspartylglutamate peptidase, those studying PCa or general oncology commonly use 
the term PSMA, which will be used here. It has been shown that PSMA is present in low 
amounts on prostate epithelial cells and is progressively up-regulated during disease 
progression in prostate tumors, in which it correlates negatively with prognosis (31–33) and 
consequently may be a promising tool for the diagnosis, detection, localization, and 
treatment of PCa. Currently, PSMA is used as an immunoscintigraphic target in the clinic to 
direct therapy to androgen-independent prostate tumors. RNA aptamers selectively targeting 
PSMA enzymatic activity have also been successful in slowing primary tumor growth in 
murine models (34, 35). Although we have previously shown that endothelial-expressed 
PSMA regulates angiogenesis (36, 37) and retinal neovascularization (38) primarily via β1 
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integrin–mediated cell adhesion, an important functional role for PSMA in PCa has not been 
demonstrated. To directly investigate the role of PSMA in PCa progression, we crossed 
FOLH1 global knockout mice (hereafter called PSMA knockout) (39) with the well-
characterized transgenic adenocarcinoma of the mouse prostate (TRAMP) murine model 
(40, 41) to study PCa tumor progression in the absence of PSMA expression.
Here, we report that expression of PSMA in prostatic epithelial cells directly underlies 
prostate tumor progression in vivo. We found that tumors in wild-type animals were larger 
and of higher grade with a higher microvessel density as compared to tumors in the PSMA 
knockout animals, which is consistent with our previous results implicating PSMA as an 
angiogenic regulator (36, 37, 42). In addition, PSMA-positive tumor cells were viable at 
greater distances from the vasculature than their PSMA knockout counterparts, suggesting 
that cell-intrinsic survival components also contribute to tumor growth. Accordingly, wild-
type tumors expressed relatively greater amounts of IGF-1R and exhibited greater activation 
of the phosphatidylinositol 3-kinase (PI3K)–AKT pathway, whereas tumors lacking PSMA 
not only had decreased IGF-1R expression but also had diverted signaling downstream of 
PI3K-AKT to the mitogen-activated protein kinase (MAPK)–extracellular signal–regulated 
kinases 1 and 2 (ERK1/2) pathway, consistent with a PSMA-dependent signaling switch. 
Moreover, manipulation of PSMA expression in mouse TRAMP-C1 cell lines and human 
PCa cell lines recapitulated this change in signaling. Analysis of publically available gene 
expression data sets from PCa samples confirmed that high PSMA expression was predictive 
of a high Gleason score. In addition, patient samples with high PSMA expression and high 
Gleason scores displayed a prosurvival gene expression signature with increased expression 
of the antiapoptotic marker survivin and IGF-1R, consistent with a role for PSMA in the 
regulation of signal transduction in human PCa disease as well. Therefore, in addition to its 
role as a PCa marker and target, our results indicate that increasing amounts of PSMA in 
prostate tumor epithelium serve to drive prosurvival mechanisms and thus identify it as a 
functional regulator of prostate tumor progression. These findings also suggest that PSMA-
positive tumors may be more sensitive to PI3K pathway inhibitors and less sensitive to 
MAPK pathway inhibitors.
RESULTS
Previous studies of PSMA in PCa progression have primarily involved manipulation of 
PSMA expression in established tumor cell lines. To genetically address the contribution of 
PSMA to PCa development and progression, we crossed PSMA knockout mice with 
TRAMP transgenic mice. The TRAMP murine model of PCa has been extensively 
characterized and closely mimics PCa progression seen in patients from onset of hyperplasia 
to adenoma and, eventually, to adenocarcinoma (40, 41). TRAMP mice uniformly and 
spontaneously develop autochthonous prostate tumors after the onset of puberty consequent 
to the expression of the SV40 T antigen from the rat probasin promoter (41, 43). Disease 
onset occurs by 8 weeks of age, adenoma occurs by 18 weeks, and most tumors are poorly 
differentiated and highly invasive by 30 weeks (40, 41). Considered within the range of their 
validity, TRAMP mouse models have been predictive of clinical outcome. To directly assess 
the contribution of PSMA to PCa initiation and progression, we initially determined that 
PSMA was expressed in tumors from the TRAMP model. F2 progeny of PSMA knockout or 
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wild-type mice bred to TRAMP transgenic animals produced tumors that were either 
positive or negative for PSMA expression (Fig. 1A). Western blot analysis of tumor lysates 
derived from PSMA knockout animals verified the complete loss of PSMA protein 
expression (Fig. 1B). Analysis of body and total prostate weights of wild-type and PSMA 
knockout animals at the established time points of 8, 18, and 30 weeks of age showed that 
although overall body weight at 18 weeks of age was significantly different between 
genotypes, this discrepancy was not seen at 8, 30, or >33 weeks of age (Fig. 1C). 
Conversely, the total prostate weights of wild-type mice were substantially higher than those 
of the PSMA knockout mice older than 30 weeks.
Considering the differences between mouse and human prostate tissue and the differences in 
rates at which lesions can progress in each lobe of the prostate (44), we assessed the dorsal, 
ventral, and anterior lobes separately at each time point using a double-blind, numerical 
scoring system based on histologically distinguishable patterns of growth and disease (45). 
Briefly, on the basis of a histological grading scheme for TRAMP mice developed by Suttie 
et al. (45), hematoxylin and eosin (H&E)–stained tissues were graded as hyperplasia (grades 
1 to 3), adenoma (grades 4 to 5), or adenocarcinoma (grade 6). Within each grade, a 
distribution was assigned as focal, multifocal, or diffuse (Table 1).
At 8 weeks of age (the initial time point), in the anterior lobe, the minimum lesion grade was 
the same for both the wild-type and PSMA knockout tumors (grade 2, focal), and the most 
severe grade was higher in the wild-type mouse tumor (grade 3, diffuse). In the dorsal lobe, 
the highest grade observed (grade 4, diffuse) was once again in the wild-type tumor, and the 
lowest grade (grade 2, multifocal) was observed in the PSMA knockout tumor. Finally, in 
the ventral lobe, the highest grade was seen in the wild-type tumor (grade 4, multifocal), and 
the lowest grade observed was identical for both experimental conditions (Fig. 1D).
At 18 weeks of age (the intermediate time point), in the anterior lobe, although the minimum 
lesion grade was the same for the wild type and PSMA knockout (grade 3, focal), the most 
severe grade was significantly higher in the wild-type mouse tumor (grade 5, multifocal) 
than in the PSMA knockout (grade 4, focal). In the dorsal lobe, the minimum lesion grade 
was slightly higher in the wild type (grade 3, diffuse) than in the PSMA knockout (grade 3, 
multifocal). However, the maximum grade was significantly higher in the wild type (grade 5, 
multifocal) than in the PSMA knockout (grade 4 diffuse). Finally, in the ventral lobe, the 
maximum and minimum grades were identical for both conditions; however, the distribution 
of the grades was significantly different with most wild-type tumors having a higher grade 
(Fig. 1E).
At 30 weeks of age (the final time point), in the anterior lobe, the minimum grade of the 
wild type (grade 4, focal) remained slightly higher than that of the PSMA knockout (grade 3, 
diffuse). However, the highest grade was identical for both conditions (grade 6, diffuse). In 
both the dorsal lobe and anterior lobe, the maximum and minimum grades were identical 
(Fig. 1F).
To resolve the difference in grade and distribution between the wild type and PSMA 
knockout at the 8, 18, and 30 weeks of age, the data were combined and represented by a 
Caromile et al. Page 4
Sci Signal. Author manuscript; available in PMC 2017 August 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
“distribution-adjusted lesion grade,” which was calculated by assigning a number to each 
successive rank (for example, 0 = normal; 1 = grade 1, focal; 2 = grade 2, multifocal; … and 
so on, whereby 18 = grade 6, diffuse) (Table 2). Proliferative lesions were present in all mice 
by 8 weeks; however, the PSMA knockout clearly demonstrated less severe pathology at 8 
and 18 weeks. There was no statistical difference in tumor score between wild-type and 
PSMA knockout tumors by 30 weeks, likely indicating that the tumors had progressed to a 
point beyond the ability to distinguish any differences. Therefore, we chose to focus our 
subsequent experiments on whole prostate tissues at the time point of 18 weeks of age.
To quantitatively confirm our observation that the lack of PSMA delayed tumor 
development, we measured expression of established markers of cancer progression. 
Survivin is a member of the inhibitor of apoptosis family that is highly abundant in most 
solid tumors where it supports tumor cell survival but is absent in normal, nonmalignant 
cells (46). Relevant to our study, increased survivin abundance has been associated with 
resistance to antiandrogen therapy in advanced PCa (46). Survivin prevents the proteolytic 
cleavage of procaspase-3 to its activated form to inhibit apoptosis, and thus, a reduction in 
full-length caspase-3 levels is an independent marker of tumor progression (46). Assessment 
of the 18-week-old tumor lysates showed significantly increased abundance of survivin (Fig. 
2A) and concomitantly decreased cleaved caspase-3 (Fig. 2B) in the wild-type prostate 
tumors, consistent with increased disease progression and supporting our observation that 
PSMA promotes a more aggressive PCa phenotype.
We have previously shown that PSMA regulates endothelial activation in angiogenesis (36) 
and in retinal neovascularization (38). To assess the effects of PSMA on the formation of 
tumor vasculature, we quantified endothelial-specific CD31 abundance by 
immunohistochemistry in the 18-week-old tumors and saw a significant decrease in CD31 
staining in prostate tumors from PSMA knockout mice in agreement with our previous 
studies (Fig. 2C). However, a closer examination revealed marked structural and 
morphological differences in vessel structure between genotypes. Vessels in wild-type 
tumors were irregularly branched, tortuous, random, and dilated, a phenotype consistent 
with tumor vessel angiogenesis. By contrast, vessels in tumors lacking PSMA appeared 
more regular and organized, a phenotype referred to as normalized, suggesting that PSMA 
also contributes to the dysregulated vessel growth characteristic of tumor angiogenesis. 
Tumor vessel “normalization” results in better perfusion, reduced hypoxia, and presumably 
increased tumor growth (47), which is in contrast to our findings. To functionally confirm 
that vasculature lacking PSMA is more normalized, we assessed relative hypoxia levels by 
measuring abundance of the enzyme carbonic anhydrase IX (CA9), which is strongly 
induced in response to hypoxia, particularly in hypoxic solid tumors that are refractory to 
conventional therapies (48). Consistent with our observation of more normalized blood 
vessels, lysates from PSMA knockout tumors exhibited significantly lower amounts of CA9 
(Fig. 2D), indicating that these tumors are indeed less hypoxic than their wild-type 
counterparts. Further histologic examination indicated that both wild-type and PSMA 
knockout tumors contained defined areas of viable cells immediately adjacent to capillaries 
surrounded by a perimeter of necrotic cells (granular area). However, the viable cell area 
(measured as the distance from the capillary to the necrotic region) was more than 30% 
greater in the wild-type versus PSMA knockout tumors (Fig. 2E). Thus, wild-type cells 
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apparently are able to remain viable at oxygen concentrations that are toxic for normal cells 
and can survive at greater distances from the vasculature than cells lacking PSMA despite 
increased tissue hypoxia. TUNEL (terminal deoxynucleotidyl transferase–mediated 
deoxyuridine triphosphate nick end labeling) staining indicated that cell death by apoptosis 
was markedly less in the wild-type compared to the PSMA knockout tumors (Fig. 2F), 
which is supported by an increased amount of cleaved poly(adenosine 5′-diphosphate-
ribose) polymerase (PARP) Asp241, a marker of apoptosis (Fig. 2G) (9). Consequently, 
immunohistochemical analysis to assess cell proliferation exhibited decreased abundance of 
the cell proliferation marker Ki67 in PSMA knockout tumors (Fig. 2H). Together, these 
observations indicate that although vessels are more normalized and tumor tissues are less 
hypoxic in the absence of PSMA, PSMA expression in tumor cells appears to confer an 
intrinsic survival advantage that is more beneficial to tumor growth than a favorable vessel 
phenotype.
Tumor cells often escape apoptosis by modifying the expression or activation status of RTKs 
to induce hyperactivation of prosurvival signal transduction pathways and preserve cell 
integrity (49). To determine whether the presence of PSMA in advanced PCa may induce 
similar prosurvival mechanisms, we assayed the activation status of a panel of RTKs that are 
commonly altered in solid tumors (Fig. 3A) (50). Whereas protein abundance of the RTKs 
VEGFR2 (vascular endothelial growth factor receptor 2) and EGFR2 (epidermal growth 
factor receptor 2) was unchanged in both the wild-type and PSMA knockout PCa tumors, 
wild-type PCa tumors displayed higher amounts of total IGF-1R, consistent with our 
prosurvival phenotype. In addition, elements of the PI3K-AKT prosurvival pathway PDK1-
Ser241, and AKT-Thr308 were stimulated and amounts of GSK-3β-Ser309 were decreased 
(Fig. 3B). Surprisingly, signal transduction in the PSMA knockout prostate tumors was 
completely reversed, where the MAPK-ERK1/2 pathway is clearly enhanced, as illustrated 
by increased growth factor receptor–bound protein 2 (GRB2) adaptor protein levels and 
ERK phosphorylation in PSMA knockout tumors compared to wild type (Fig. 3C).
As a relatively slow-growing tumor, primary PCa can be present for years before detection, 
and latency to metastasis can also be quite protracted. However, a percentage of patients 
present with a more rapidly growing, aggressive form of PCa that has a markedly worse 
diagnosis. We observed that tumor progression and growth are delayed in PSMA knockout 
animals, although tumors from wild-type and PSMA knockout animals are histologically 
indistinguishable at the extended 30-week time point, suggesting either that the pathway 
switch we see at 18 weeks of age is eventually reversed, that a small percentage of cells do 
not switch and eventually outgrow the slower growing population, or that tumors with low 
levels of PSMA may correlate with the slower, less aggressive tumor type. To determine the 
signaling status of PSMA knockout tumors at 30 weeks of age, we assessed activation levels 
of the AKT versus ERK signaling pathways. Western blot analysis determined that AKT 
phosphorylation Thr308 is maintained in the long term in PSMA wild-type tumors but not in 
PSMA knockout (Fig. 3D), consistent with a permanent pathway switch in the absence of 
PSMA and perhaps indicating that tumors presenting with low PSMA abundance may be a 
marker of the slower, less aggressive form of PCa.
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To confirm that this pathway switch is strictly dependent on PSMA, we functionally 
manipulated PSMA by CRISPR (clustered regularly interspaced short palindromic repeats) 
deletion in both the human 22Rv1 and murine TRAMP-C1 cell lines (Fig. 4A and figs. S1 
and S2) or small interfering RNA (siRNA) knockdown or by disrupting intracellular 
interactions with a PSMA-specific N-terminal blocking peptide in TRAMP-C1 cells (fig. 
S3) (36), which consistently resulted in effects on signaling via the AKT pathway (Fig. 4, A 
and B). Overexpression of human PSMA in the PSMA knockout human PC-3 PCa cell line 
altered signaling pathways similar to that we observed in wild-type tumors, demonstrating 
that these mechanisms are operative in human PCa (Fig. 4C). Together, our data suggest that 
in both the in vivo murine TRAMP model and the in vitro tumor cell lines, PSMA directly 
contributes to tumor progression by affecting IGF-1R signal transduction to result in a 
signaling pathway switch that promotes tumor survival, growth, and progression.
Aberrant or disrupted interactions between components of signaling pathways are frequently 
responsible for alterations in downstream signaling pathways during tumorigenesis (51). 
One such example is cooperation between IGF-1R and β1 integrin that regulates cancer cell 
growth, survival, and invasion (52). We have previously shown that PSMA regulates 
angiogenesis by modulating β1 integrin-dependent focal adhesion kinase (FAK)–Tyr925 
phosphorylation and signal transduction in endothelial cells (36, 37), and here, we 
demonstrate that PSMA affects IGF-1R signaling pathways in PCa cell lines (Fig. 5), 
suggesting that PSMA may affect IGF-1R/β1 integrin/FAK cross-talk. To further investigate 
PSMA in this capacity, we examined the aspects of the complex containing scaffolding 
protein RACK1 (receptor for activated C kinases) that facilitates cooperation between β1 
integrin and RTKs (18, 19, 21, 53). Stable IGF-1R/RACK1/β1 integrin complex formation 
leads to activation of the ERK pathway, and disruption of this complex stimulates the AKT 
survival pathway (53–56), analogous to the PSMA-dependent pathway switch. Initial 
evaluation of potential PSMA effects on FAK status in PCa cells showed that whereas FAK 
is markedly phosphorylated on FAK-Tyr397 in the wild-type 22Rv1 cell lines and tumors, 
elimination of PSMA expression in 22Rv1-Crispr-PSMAknockout cells or PSMA knockout 
tumors clearly switches FAK tyrosine phosphorylation to FAK-Tyr925 (Fig. 5, A and B). 
This result confirms a role for PSMA in integrin activation in PCa cells and is consistent 
with observations of FAK-Tyr397 hyperphosphorylation in cells where the IGF-1R/
RACK1/β1 integrin complex is disrupted by IGF-1R mutation (21). Furthermore, 
immunoprecipitation of PSMA followed by Western blot analysis demonstrated that PSMA 
physically associates with RACK1 and IGF-1R in prostate cell lysates (Fig. 5, C and D) and 
that the association between RACK1 and β1 integrin is increased when PSMA is deleted 
(Fig. 5E). In further support of this notion, ligation of integrins by the addition of 
fibronectin, which is reported to enhance complex formation and FAK-Tyr925 activation in 
breast cancer cells (18), leads to increased FAK-Tyr925 and ERK activation in control 22Rv1 
PCa cells expressing PSMA (Fig. 5, F and G). Together, these results support a model where 
the progressive up-regulation of PSMA expression in PCa tumors serves to alter the IGF-1R/
RACK1/β1 integrin complex, leading to alterations in FAK phosphorylation, AKT 
activation, and enhanced PCa progression (Fig. 6). The dependence of TRAMP tumors on 
the AKT pathway is supported by studies in which systemic treatment of TRAMP transgenic 
mice with AKT inhibitors invariably inhibits tumor growth and progression (57–61).
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To further investigate the potential link between PSMA expression levels and tumor 
progression in human PCa, we examined publically available PCa gene expression data sets 
[National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) 
(www.ncbi.nlm.nih.gov/geo/) and SEEK (http://seek.princeton.edu)] to determine (i) 
whether PSMA abundance is predictive of increased Gleason score and (ii) whether samples 
with high PSMA and Gleason score display a more prosurvival gene expression phenotype, 
as we observed in mouse tumors (Fig. 7). A transcriptional analysis of 59 PCa and 39 
matched benign tissue samples in the NCBI GEO data set GSE32571 compared tumor 
samples with a higher Gleason score (4 + 3 and higher) against those with a lower score (3 
+ 4 and below). Further analysis using GEO2R (data file S1) showed that high PSMA 
abundance was significantly associated with a higher Gleason score when compared to 
benign tissue (Fig. 7, A and B). Furthermore, changes in IGF-1R, survivin, and caspase-9, 
which is involved in the activation of caspases responsible for the initiation of apoptosis, 
support our murine data (Fig. 7, C and D). Together, these observations support the 
translational relevance of our findings regarding the role of PSMA in PCa progression and 
highlight that the identification of novel oncogenic and druggable pathways in patient 
subgroups with poor prognosis may promote the development of tumor-specific, targeted 
therapeutic approaches.
DISCUSSION
The striking up-regulation of PSMA expression during PCa progression and its correlation 
with patient outcome have been recognized for many years (62). Numerous 
immunohistochemical investigations have demonstrated extensive PSMA expression in 
prostate adenocarcinomas and metastases (63–65), but its functional contribution to any 
aspect of PCa has remained enigmatic. Studies manipulating PSMA concentrations in PCa 
cell lines have produced contradictory results; one determined that the enzymatic activity of 
PSMA inhibited PCa cell invasion (66), whereas others found that PSMA expression 
increased PCa cell invasion in vitro (67). Neither study addressed the underlying 
mechanism. An interesting in vivo model that used transplanted prostate tissue from PSMA-
overexpressing transgenic mice found that PSMA expression correlated with the 
development of small atypical glands representative of adenocarcinoma, but these PIN-like 
lesions never progressed to cancer and, again, molecular mechanism was not investigated 
(68). Here, we directly address whether the increased abundance of PSMA in advanced 
prostate tumors is indicative of a functional role for this cell surface peptidase in PCa 
progression. Using the well-characterized TRAMP model of PCa (69) and global PSMA 
knockout mice (39), we demonstrate that PSMA promotes dysregulation of IGF-1R signal 
transduction, resulting in a shift in downstream signal transduction pathways that promote 
PCa tumor progression in vivo.
The IGF-1R has emerged as a molecule with important roles in cancer biology (7) and is 
overexpressed in a high percentage of primary and metastatic tumors, including PCa (4, 5, 7, 
70). Most of the studies on IGF-1R signaling have focused on its role in the differential 
activation of two important intracellular signaling pathways: the MAPK-ERK pathway, 
which regulates cell proliferation, differentiation, and tissue homeostasis, or the PI3K-AKT 
cascade, which promotes cell survival, metabolism, antiapoptosis, and differentiation (6, 71). 
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It is known that ligand binding to IGF-1R triggers the phosphorylation of multiple tyrosine 
sites within the IGF-1R activation loop, creating a docking site for the signaling molecules 
IRS-1 and Shc. These interactions subsequently activate the PI3K-AKT and MAPK-ERK 
cascades through IGF-1R recruitment of either the P85 subunit of PI3K or the Ras-activating 
Grb2/ SOS complex (72).
We see a high abundance of IGF-1R in wild-type tumors, which is markedly reduced upon 
loss of PSMA. A retrospective analysis of next-generation sequencing data from about 900 
breast cancer samples showed that a large majority of tumors contained genetic alterations 
that resulted in either the activation of PI3K pathway or the repression of the MAPK 
pathway, but rarely contained both (73). A third group of tumors harbored amplifications or 
mutations resulting in increased expression of genes encoding the receptor-type tyrosine 
kinases IGF-1R, EGFR, or ERB-B2, which were accompanied by PI3K activation and 
MAPK repression, whereas the genes encoding components of the PI3K and MAPK 
pathways were intact. The authors interpreted this mutually exclusive, “mirror” pattern of 
genetic alterations to illustrate the intimate interregulation of the RTK, PI3K, and MAPK 
pathways and hypothesized that the primary role of RTK up-regulation in tumors may be to 
regulate these kinases, thereby affecting the tumor cell balance among proliferation, self-
renewal, and differentiation (73). Our study show a very similar signaling signature in PCa 
with increased IGF-1R abundance, activation of the PI3K, and down-regulation of MAPK 
pathways in the presence of PSMA. However, in our model, rather than IGF-1R up-
regulation by mutation or amplification, we demonstrate that IGF-1R abundance is PSMA-
dependent and is potentially responsible for PI3K activation, thus controlling primary tumor 
advancement. Amounts of IGF-1R–mediated signaling do not change significantly during 
primary tumor progression in the TRAMP mice on the wild-type (PSMA+) background (74), 
and treatment of wild-type TRAMP mice with various AKT inhibitors reliably reduces 
tumor size and progression (57–61), further implicating PSMA as a driver of IGF-1R/AKT 
signaling and prostate tumor progression. Therefore, although the IGF-1R–dependent 
pathway switch we observe in advancing tumors is not unprecedented, its connection with 
this highly verified marker of PCa progression provides novel mechanisms, whereby PSMA 
expression promotes a more aggressive, apoptosis-resistant prostate tumor phenotype.
During cancer development, frequent cross-talk between receptor-driven signal transduction 
pathways often occurs and results in alterations in downstream signal transduction pathways 
(51). We have previously shown that PSMA regulates angiogenesis by modulating integrin 
signal transduction and β1 integrin–dependent FAK-Tyr925 phosphorylation in endothelial 
cells (36, 37, 42) and show here that its expression alters FAK phosphorylation and IGF-1R 
signaling pathways in PCa cells (Fig. 6). A large body of evidence has suggested that 
cooperation between β1 integrin and RTKs regulates cancer cell growth, survival, and 
invasion in many tumor types (10–30, 52) and has been shown to involve the multifunctional 
scaffolding protein RACK1 (18–21). RACK1 physically interacts with multiple partners, 
thereby influencing their function by modifying stability, activity, or interactions with other 
proteins [reviewed in (75)]. Pertinent to this study, in breast and prostate tumor cells, 
RACK1 has been shown to promote migration and cell survival by scaffolding IGF-1R and 
β1 integrin to integrate signaling via recruitment of signaling proteins such as SHC and 
SHP2 (18–20, 26), whereas interruption of the IGF-1R/RACK1 interaction leads to 
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activation of AKT (21). In prostate tumor cells, we find that RACK1 and IGF-1R associate 
with PSMA and that deletion of PSMA in PCa cell lines enhances the β1 integrin/RACK1 
interaction, suggesting that PSMA may regulate integrin/IGF-1R cross-talk via its 
interaction with RACK1. Because binding of some proteins to RACK1 is competitive, our 
data are consistent with a model where the PSMA/RACK1 interaction disrupts or alters the 
IGF-1R/RACK1/β1 integrin complex, leading to aberrant cross-talk between β1 integrin and 
IGF-1R that favors PI3K-AKT activation in our PSMA wild-type tumor cells. Finally, 
although PSMA is expressed primarily in prostate and neuroendocrine cancers, the 
IGF-1R/β1 integrin axis has been implicated in many tumor types, and RACK1 has been 
demonstrated to interact with numerous, disparate proteins from cytoplasmic (PP2A, p85 
PI3K, SHP-2, SRC, smoothened, Stat3, and TROP-2) to various cell surface proteins 
(PSMA, IGF-1R, and IR) (18–21, 23, 26, 53, 76). Thus, our findings regarding the 
regulation of signal transduction by interaction of PSMA with RACK1/IGF-1R will likely 
extend to other tumor types and cell surface molecules.
Historically, in oncology, PSMA has been studied as a reliable clinical biomarker for the 
diagnosis, detection, localization, and management of PCa. A number of PSMA-targeted 
small and low–molecular weight inhibitors and antibodies have proven valuable in providing 
high image quality in diagnostic imaging and delivering high local doses of 
radiopharmaceuticals [reviewed in (77–79)]. Alternatively, targeting the PSMA-dependent 
mechanisms driving PCa tumor progression may provide a novel paradigm for the 
development of therapeutic strategies for treatment by targeting both progression and 
vascularization because we have shown that inhibition of PSMA with the inhibitor 2-PMPA 
impairs integrin activation, endothelial cell adhesion, and angiogenesis (36, 37, 42). Ligand 
engagement of PSMA induces its internalization, and therefore, it also presents an effective 
delivery system for therapeutic molecules (80). Recent preclinical characterization of 
PSMA-targeted RNA aptamers that bind to and block the enzymatic activity of PSMA has 
been described that specifically target therapies to primary tumors and disseminated PCa cell 
lines in vivo (35, 81, 82). Finally, TRAMP mice lacking PSMA develop more slowly 
growing tumors but eventually proceed to high-grade pathologies, likely because of their 
dependence on the weaker but still oncogenic Ras/MAPK pathway. Together with these 
observations, our study suggests the potential for design of combination therapies that 
exploit the PCa-dependent increase in PSMA expression, the proven ability of PSMA-
targeting agents to deliver payloads, and the PSMA-dependent pathway switch by agents 
designed to deliver Ras/MAPK/ERK inhibitors or siRNA directly to PSMA-expressing 
tumor cells, thereby inducing the switch to the less aggressive pathway while silencing the 
tumors’ escape mechanism. Such targeted, biology-based therapy has the potential to 
provide novel, less-toxic, and effective therapies that could have a broad positive impact on 
outcomes in PCa and in other tumors that rely on the IGF-1R/integrin axis for their 
oncogenicity.
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MATERIALS AND METHODS
Mice
All procedures used in handling mice were approved by the Animal Care Committee of 
UCONN Health in compliance with Animal Welfare Assurance. TRAMP mice on a 
C57BL6 background have been described (83) and were obtained from The Jackson 
Laboratory. C57BL6 PSMA knockout mice have been described (84) and were a donation 
from W. Heston at the Cleveland Clinic. Sibling female TRAMP mice were mated to wild-
type and PSMA knockout sibling males. The resultant female TRAMP-hemizygote PSMA 
heterozygote females were bred with PSMA knockout males to yield TRAMP-hemizygote 
PSMA knockout females, which were then bred to produce TRAMP-hemizygote PSMA 
knockout males for the study. In addition, mice from the original cohort were bred with 
PSMA wild-type males to obtain TRAMP-hemizygote PSMA wild-type males. Overall, 
male mice from the same cohort of animals (same original founders) hemizygous for the 
TRAMP transgene, either PSMA wild type or PSMA knockout (20 mice per genotype per 
time point; a total of 120 mice), were be bred and held until they reach the desired time 
points (8, 18, and 30 weeks). Mice were provided food and water ad libitum. Littermates 
were compared in all experiments.
Genotyping
Mice were genotyped for both PSMA and TRAMP by isolating DNA from tail biopsies [50 
mM tris (pH 8.8), 1 mM EDTA (pH 8.0), 0.5% Tween 20, and 3 µg of proteinase K; 50°C 
overnight and then 100°C for 10 min]. Genotype for PSMA and the TRAMP transgene has 
been described previously (83, 84).
Necropsy
Animals were euthanized by CO2 asphyxiation, in accordance with the guidelines given by 
the Animal Care Committee of UCONN Health, followed by cervical dislocation to ensure 
death. Prostate was removed as part of the whole male urogenital system and then dissected 
away from nonprostatic tissue.
Cell culture
TRAMP-C1, 22RV1, and PC-3 cells were obtained from the American Type Culture 
Collection (ATCC). Unless otherwise noted, TRAMP-C1 were cultured in Dulbecco’s 
modified Eagle’s medium supplemented with 5% fetal bovine serum (FBS), 5% Nu-Serum 
IV, 1% penicillin-streptomycin (pen-strep), bovine insulin (0.005 mg/ml), and 10 nM de-
hydroisoandrosterone. 22RV1 were cultured in RPMI supplemented with 10% FBS, and 1% 
pen-strep. PC-3 cells were cultured in F-12K supplemented with 10% FBS and 1% pen-
strep. All cells were maintained at 37°C, 5% CO2.
Apoptosis evaluation by TUNEL assay
For the evaluation of apoptosis, deparaffinized and rehydrated 6-µm-thick sections of whole 
prostate tumor sections from PSMA wild-type and PSMA knockout mice at 18 weeks of age 
were incubated with proteinase K (20 µg/µl) in 10 mM tris-HCl (pH 7.4) at 37°C for 20 min, 
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and apoptotic cells were detected by the TUNEL method by using the ApopTag Peroxidase 
In Situ Apoptosis Detection system (EMD Millipore) according to the manufacturer’s 
protocol. Negative controls were prepared by incubating slides without terminal 
deoxynucleotidyl transferase. Mouse small intestine was used as a positive control. To 
visualize the immunoreaction products, sections were incubated with a mixture of DAB 
(3,3′-diaminobenzidine) and H2O2. Slides were examined and TUNEL-positive cells were 
counted with hematoxylin. Images were acquired using a Zeiss LSM 510 META based on 
an Axiovert 200 microscope and processed using Zeiss AxioVision software.
Antibodies
Antibody against PSMA for immunohistochemistry was purchased from Zymed (517–
3294). PSMA monoclonal antibody 3E2 was a kind gift from Memorial Sloan Kettering. 
Rabbit monoclonal PSMA (D718E; cat. no. 12815) and RACK1 (D59D5; cat. no. 5432) 
were purchased from Cell Signaling Technologies (CST). Antibody against CD31/
PECAM-1 was purchased from Santa Cruz Biotechnology (SCB; sc-1506). Antibody 
against Ki67 was purchased from Abcam (15580). Antibody against GRB2 was purchased 
from SCB (sc-503). The following antibodies were purchased from CST: IGF-1R (cat. no. 
9750), β1 intergrin (cat. no. 34971), survivin (cat. no. 71G4B7), caspase-3 (cat. no. 9665), 
CA9 (cat. no. 5648), PDK1-Ser241 (cat. no. 3438), AKT-Thr308 (cat. no. 13038), AKT-
Ser473 (cat. no. 4060), GSK-3β-Ser9 (cat. no. 5558), total AKT (cat. no. 4691), pERK1/2 
(cat. no. 197G2), total ERK (cat. no. 9102), and β-actin (cat. no. 3700).
Western blot analysis
Mouse prostate tumor tissues were removed, weighed, and then washed three times in cold 
phosphate-buffered saline (PBS). A portion of the tumor was the incubated in 1× RBC lysis 
buffer for 10 min (Thermo Fisher Scientific), and the remaining portion of the tumor was 
saved for RNA extraction and/or paraffin embedding. Samples were then centrifuged at 1000 
rpm for 2 min, and the supernatant was removed. The tumor tissue was then homogenized 
with a PowerGen 125 tissue homogenizer (Thermo Fisher Scientific) in lysis buffer 
containing 50 mM tris (pH 7.4), 150 mM NaCl, 1% NP-40, plus the tyrosine phosphatase 
inhibitor Na3VO4 (1 mM), and the protease inhibitors phenylmethyl-sulfonyl fluoride 
(PMSF) (1 mM), pepstatin (1 mM), and aprotinin (1.5 mg/ml). After incubation at 4°C for 
20 min, nuclear and cellular debris were removed by microcentrifugation at 14,000 rpm for 
10 min at 4°C. Total protein concentrations were determined by the BCA Assay kit (Thermo 
Fisher Scientific), and 30 to 50 µg of each sample was electrophoresed on a 4 to 20% tris-
Hepes SDS gradient gel (Pierce) and then electroblotted onto Protran nitrocellulose 
membranes (Thermo Fisher Scientific) using a semidry transfer apparatus. Membranes were 
blocked with tris-buffered saline, 5% bovine serum albumin (BSA) for 30 min, washed, and 
incubated with indicated primary and secondary antibodies for 12 hours and 30 min, 
respectively. The membranes were washed extensively with tris-buffered saline and 0.1% 
Tween 20 after secondary antibody incubation and detected using the ECL Western blotting 
kit (Thermo Fisher Scientific) according to the manufacturer’s suggested protocol.
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Immunohistochemistry
Mouse prostate tissues were fixed overnight in 4% paraformaldehyde at 4°C and were 
paraffin-processed. Slides containing 6-µm-thick sections were deparaffinized and 
rehydrated. Antigen retrieval was conducted using 10 mM sodium citrate (pH 6.0) in a 
pressure cooker. Endogenous peroxidase activity was quenched by incubating slides for 15 
min in 0.3% H2O2. Slides were blocked in 1% BSA for 30 min at room temperature in a 
humidified chamber and then incubated with the specified primary antibody overnight in a 
humidified chamber. Slides were washed in PBS. Biotinylated secondary antibody (Vector 
Laboratories) in 1% BSA was applied, and slides were incubated for 1 hour at room 
temperature in a humidified chamber. Slides were washed again, and Vectastain Elite ABC 
kit (Vector Laboratories) was applied for 30 min. Slides were developed with NovaRED 
(Sigma-Aldrich) and counterstained with hematoxylin (Vector Laboratories) and then 
dehydrated and mounted under Cytoseal 60. Images were acquired using a Zeiss LSM 510 
META based on an Axiovert 200 microscope and processed using the Zeiss AxioVision 
software.
PSMA knockdown in TRAMP-C1 by siRNA
siRNA constructs were designed from the mouse Folh1 GenBank sequence BC119604.1 
using the Oligoengine 2.0 software and cloned into the mammalian expression vector 
pSUPER.retro.puro at Bg lII/ Hind III (OligoEngine) according to the manufacturer’s 
directions. To generate the retrovirus, plasmid DNA (10 µg) was transfected into the Phoenix 
Amphotropic retrovirus packaging cell line (ATCC) by lipid transfection. Medium 
containing virus was collected 48 hours after transfection. TRAMP-C1 cells were infected 
and selected in puromycin (5 µg/ml; Sigma-Aldrich). Reduction of PSMA transcript level 
was evaluated by reverse transcription polymerase chain reaction (PCR) and real-time PCR 
followed by Western blot evaluation of PSMA protein expression.
PSMA siRNA primers were as follows: 581, 5′-GATCCCCGAA-
GATCAGTTGTTCTGGGTTCAAGAGACCCAGAACAACT-GATCTTCTTTTTA-3′ 
(forward) and 5′-AGCTTAAAAAG-
AAGATCAGTTGTTCTGGGTCTCTTGAACCCAGAACAACT-GATCTTCGGG-3′ 
(reverse); 472, 5′-GATCCCCATGTAGTGCCAC-
CATACAGTTCAAGAGACTGTATGGTGGCACTACATTTTTTA-3′ (forward) and 5′-
AGCTTAAAAAATGTAGTGCCACCATA-
CAGTCTCTTGAACTGTATGGTGGCACTACATGGG-3′ (reverse); 348, 5′-
GATCCCCGTCTTGCTGTCCTATCCAATTCAAGAGATTG-
GATAGGACAGCAAGACTTTTTA-3′ (forward) and 5′-AGCT-
TAAAAAGTCTTGCTGTCCTATCCAATCTCTTGAATTGGATAG-
GACAGCAAGACGGG-3′ (reverse).
CRISPR knockout of PSMA in PCa cell lines TRAMP-C1 and 22RV1
PSMA CRISPR/Cas9 constructs were created in both TRAMP-C1 and 22RV1 cell lines 
using the lentiCRISPRv2 plasmid #52961 (Addgene) (85,86). To guard against genome-
wide off-target effects and still maintain high target specificity, 20–base pair (bp) guide RNA 
(gRNA) was designed through the CRISPR Design (http://crispr.mit.edu) using the target 
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sequence from either the mouse Folh1 GenBank sequence BC119604.1 or the human 
FOLH1 GenBank sequence NG_029170.1 as input; scramble gRNA was also designed as a 
control: gRNA for PSMA 22RV1, 5′-TCACGAAACCGACTCGGCTG-3′; gRNA scramble 
22RV1, 5′-CAGTCGGGCGTCATCATGAT-3′; gRNA for PSMA TRAMP, 5′-
GCAGGACAGAGACTCCGCGG-3′; and gRNA scramble TRAMP, 5′-
CAGTCGGGCGTCATCATGAT-3′. In the genome, gRNA sequences were flanked on the 
3′ end by a 3-bp NGG protospacer adjacent motif sequence. The gRNAs were 
phosphorylated, annealed, and cloned into a dephosphorylated lentiCRISPRv2 at BSMB1 
according to the manufacturer’s directions (Addgene). To generate the lentivirus, the 
plasmid lentiCRISPRv2 containing either the human or the mouse PSMA or scramble 
gRNA was cotransfected (Lipofectamine 2000, Thermo Fisher Scientific) into HEK293(F)T 
cells along with the packaging plasmids pMD2.G (#12259, Addgene) and psPAX2 (#12260, 
Addgene). The culture medium containing virus was collected 48 h after transfection. 
22RV1 and TRAMP-C1 cells were infected and selected in puromycin (2 or 5 µg/ml, 
respectively) (Sigma-Aldrich). Validation of genetic modification in individual TRAMP-
CRISPR-PSMAknockout and 22RV1-CRISPR-PSMAknockout clones was assessed by PCR 
amplification of the targeted loci and subsequent sequencing. Chromatographs were 
compared to wild-type cells using TIDE (Tracking of Indels by Decomposition; https://tide-
calculator.nki.nl/) analysis to identify the mutations in the two alleles (figs. S1 and S2) (87).
TaqMan (real-time quantitative reverse transcription PCR) analysis
Total RNA from cultured cells was isolated using RNeasy (Qiagen). RNA was reverse-
transcribed by standard methods using reverse transcriptase (Invitrogen). For TaqMan real-
time PCR, PSMA and 18S primers, TaqMan Gene Expression Assay probe, and primer sets 
were purchased from Applied Biosystems. An Applied Biosystems Prism 7500 Fast Real-
time PCR system (Applied Biosystems) was used with the default thermal cycling program 
(95°C for 20 s, followed by 40 cycles at 95°C for 3 s and 60°C for 30 s). Reactions were 
performed in triplicate and normalized to the level of 18S RNA transcript.
Primers
PSMA primers were as follows: forward IntA, 5′-ATTCAATCCTGCT-CAGACCC-3′; 
forward Neo-S, 5′-AGCAGGCATGCTGGGGATGC-3′; reverse S49, 5′-
GTAGAAGAGGAACTGCTGAGGA-3′. TRAMP primers were as follows: forward 
TRAMP SV5, 5′-CAGAGCAGA-ATTGTGGAGTGG-3′; reverse TRAMP SV1, 5′-
GGACAAACCA-CAACTAGAATGCAGTG-3′.
PSMA blocking peptide
A peptide containing the C-terminal domain of PSMA was synthesized by Invitrogen. A C-
terminal free acid and an N-terminal free amine were added to the completed peptides to aid 
in transfection. Mouse PSMA, MWNALQDRDSAEVLGHRQR; scramble, 
ESAMTWVRLRNP-TADRLAH. For peptide transfections, 1 mg of the PSMA and 
scrambled peptides were transfected into 2×105 to 4×105 TRAMP C-1 cells using 
BioPORTER (Qiagen) protein delivery system according to the manufacturer’s 
recommendations. Cotransfection of a positive control fluorescein isothiocyanate (FITC)–
containing protein ensured appropriate transfection efficiency (fig. S4). Cells were incubated 
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for 24 hours, washed in PBS, and lysed in 1% NP-40, 150 mM NaCl, 50 mM tris-HCl (pH 
7.4) buffer plus the tyrosine phosphatase inhibitor Na3VO4 (1 mM), and the protease 
inhibitors PMSF (1 mM), pepstatin (1 mM), and aprotinin (1.5 mg/ml). After incubation at 
4°C for 20 min, nuclear and cellular debris were removed by microcentrifugation at 14,000 
rpm for 10 min at 4°C.
Stimulation of adherent and nonadherent cells
For analysis of signaling responses affected by the ligation of integrins in 22RV1-CRISPR-
PSMAknockout adherent cells, the cells and scramble control were washed with PBS and 
starved from serum for 4 hours before being stimulated with culture medium containing 
10% FBS. For analysis of signaling responses affected by the ligation of integrins in 
nonadherent cells, confluent 22RV1-CRISPR-PSMAknockout cells and scramble control were 
detached with trypsin and then washed with PBS. Cells were resuspended in serum-free 
medium containing 5% ECM Gel (Sigma-Aldrich) and maintained in suspension for 4 hours 
before stimulation with culture medium containing 10% FBS.
Preparation of cellular protein extracts and immunoprecipitation
To study the interaction of PSMA, RACK-1, IGFR-1B, and β1 integrin, cellular protein 
extracts from either 22RV1-CRISPR-PSMAknockout, scramble, or wild-type cells were 
prepared by washing cells with PBS and lysed in buffer consisting of tris-HCl (pH 7.4), 150 
mM NaCl, 1% NP-40 plus the tyrosine phosphatase inhibitor Na3VO4 (1 mM), and the 
protease inhibitors PMSF (1 mM), pepstatin (1 mM), and aprotinin (1.5 mg/ml). After 
incubation at 4°C for 20 min, nuclear and cellular debris were removed by 
microcentrifugation at 14,000 rpm for 10 min at 4°C. Protein (700 µg) was 
immunoprecipitated with either 1 µg of RACK1 (D59D5) or PSMA 3E2 antibodies and 
immunoglobulin G antibodies, with 5 µg of goat anti-rabbit immunoglobulin G Fab fragment 
as a control (Cell Signaling Technologies), and attached to protein G Dynabeads (Invitrogen) 
at 4°C with either of the prepared beads overnight. Beads were washed while attached to a 
DynaMag and eluted according to the manufacturer’s directions (Invitrogen).
Statistical analysis
All experiments in this study were repeated for a minimum of three independent 
experiments. Differences between means were analyzed using either the two-tailed Student’s 
t test or analysis of variance (ANOVA), where appropriate, and significance was set at a P < 
0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Characterization of tumors from WT and PSMA KO TRAMP mice
(A) Immunohistological characterization of PSMA distribution (brown strain) in prostate 
tumors from 18-week-old PSMA wild-type (WT) or knockout (KO) TRAMP mice. Tissues 
were counterstained with methyl green. Magnification, ×20 (WT) and ×10 (KO); scale bars, 
100 µm. (B) Western blot (IB) analysis of PSMA abundance (monoclonal antibody 3E2) in 
whole prostate tumor lysates from 18-week-old PSMA WT or KO TRAMP mice. (C) Total 
body and prostate weights in WT and PSMA KO TRAMP mice at 8,18, and 30 weeks of 
age. Data are means ± SE from 10 WT and 10 KO mice per group. *P < 0.05, paired 
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Student’s t test. (D to F) Representative images of H&E-stained sections of anterior prostate 
(AP), ventral prostate (VP), and dorsal prostate (DP) lobes from PSMA WT and PSMA KO 
mice at 8 (D), 18 (E), and 30 (F) weeks of age. n = 30 for each experimental group. 
Magnification, ×25; scale bar, 100 µm.
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Fig. 2. PSMA WT prostate tumors display a more vascularized, hypoxia-tolerant, antiapoptotic 
phenotype
(A and B) Western blotting for survivin and caspase-3 (CASP3) in whole prostate tumor 
lysates from 18-week-old PSMA WT and KO TRAMP mice. (C) Immunohistochemical 
analysis of tumor vasculature by CD31 staining, quantified for CD31+ pixel area sum from 
five nonoverlapping fields per sample using Image-Pro Plus software (hematoxylin 
counterstain). Scale bar, 50 µm. (D) Western blot analysis for CA9, a marker of hypoxia, in 
whole prostate tumor lysate from 18-week-old PSMA WT and KO mouse tumors. (E) 
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Thickness of viable layer of tumor cells from CD31-stained capillaries. PSMA WT (65 µM) 
and KO (40 µM). Tissue was counterstained with hematoxylin, and images are shown at ×20 
magnification. Scale bar, 100 µm. (F) Representative TUNEL stain to detect apoptotic cells 
(brown) in PSMA WT and KO tumor sections from 18-week-old mice. Sections were 
counterstained with hematoxylin. Analysis is representative of the number of apoptotic cells 
per field. Images are shown at ×10 and ×40 magnifications. Scale bar, 50 µm. (G) Western 
blot anaylis of cleaved PARP Asp214, a marker of apoptosis, in PSMA WT tumors compared 
to PSMA KO tumors. (H) Immunohistochemical analysis of cell proliferation (Ki67 
staining) in PSMA WT and PSMA KO tumor sections. Scale bar, 100 µm. All Western blots 
were normalized to β-actin and are presented as fold change relative to WT. Data are means 
± SE from n = 4 animals for each experimental group, with at least three experimental 
replicates. *P < 0.05, paired Student’s t test.
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Fig. 3. PSMA within the prostate tumor epithelium shifts cell signaling from an “active GRB2-
ERK1/2 pathway–inactive PI3K-AKT pathway” state to an “active PI3K-AKT pathway–inactive 
GRB2-ERK1/2 pathway” state
(A to C) Western blotting of whole prostate tumor lysates from 18-week-old PSMA WT or 
KO TRAMP mice for various RTKs (A), AKT pathway markers (B), and MAPK pathway 
markers (C). (D) Blotting for the indicated markers in tumors from 30-week-old PSMA WT 
and KO mice. Blots are representative of three experiments from n = 3 WT and 3 KO mice, 
normalized to β-actin and presented as fold change relative to WT. *P < 0.05, paired 
Student’s t test.
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Fig. 4. Manipulation of PSMA in both mouse TRAMP-C1 and human 22RV1 and PC-3 PCa cell 
lines mimic pathway switch
(A) CRISPR knockdown of PSMA in both the mouse TRAMP-C1 cell line (TRAMP-
PSMAKO) and the human 22Rv1 cell line (22RV1-PSMAKO). Western blot analysis of both 
CRISPR cell lines to examine changes in PDK-Ser241, IGF-1R, survivin, and pERK1/2 
compared to controls (Scr). (B) TRAMP-C1 cells transiently transfected with peptides 
blocking the PSMA NH2-terminal cytoplasmic tail. Western blot at 24 hours for pERK1/2, 
cleaved PARP Asp214, and survivin at 24 hours compared to the control (Scr). (C) Western 
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blot analysis of PC-3 cells expressing human PSMA (hPSMA) and empty vector (EV) 
control cell lysates to investigate changes in the previously identified signaling pathways 
(PSMA, IGF-1R, AKT-Ser380, AKT-Thr308, PDK1-Ser241, pERK1/2, survivin, and β-actin). 
All data are representative images from the mean ± SE of n = 3 for each experimental 
condition and three experimental replicates normalized to β-actin and presented as fold 
change, where WT is equal to 1. *P < 0.05, paired Student’s t test.
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Fig. 5. PSMA expression markedly alters FAK phosphorylation, and PSMA is in a complex with 
RACK1 and IGF-1R
(A) Western analysis for FAK-Tyr397 and FAK-Tyr925 in tumor lysates from 18-week-old 
WT and KO mice. (B) Western blot analysis for FAK-Tyr397 in parental WT, control 
scramble 22Rv1 cells (Scr), and 22Rv1-PSMAKO cells. (C) Immunoprecipitation (IP) of 
PSMA in WT 22Rv1 cells using PSMA monoclonal antibody or rabbit immunoglobulin G 
(IgG) control and Western blot for IGF-1R (arrow indicates band). Input refers to unbound 
fraction. (D) Immunoprecipitation of PSMA in WT 22Rv1 cells using PSMA rabbit 
monoclonal antibody or rabbit IgG control and Western blot for RACK1. (E) 
Immunoprecipitation of RACK1 in both 22Rv1-PSMAScr and 22Rv-PSMAKO cells and 
Western blot analysis for β1 integrin. (F and G) Both 22Rv1-PSMAScr and 22Rv-PSMAKO 
cells were put either not in suspension (adherent) or in suspension (nonadherent) for 2 hours 
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and assayed by Western blot for the direct activation of FAK-Tyr925 (F) and ERK (G) by 
addition of extracellular matrix (ECM) for 30 min. All data are representative images from 
the means ± SE of n = 3 for each experimental conditions and three experimental replicates 
normalized to β-actin and presented as fold change, where WT is equal to 1. *P < 0.05, 
paired Student’s t test.
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Fig. 6. Schematic of PSMA regulation of PCa signaling
(A) In the canonical pathway, a stable scaffolding complex containing β1 integrin, RACK1, 
and IGF-1R activates the FAK-Tyr925/GRB2/ERK pathway, leading to tumor cell 
proliferation, growth, and migration. (B) In WT cells, PSMA expression disrupts two 
pathways, both of which contribute to activation of the more aggressive, protumor PI3K-
AKT pathway. PSMA physically associates with IGF-1R and RACK1, consistent with 
PSMA disrupting the scaffolding complex, which leads to FAK-Tyr397 
hyperphosphorylation (“a”), and PSMA expression reverses the phosphorylation of FAK-
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Tyr925, which is required for FAK/GRB2 interactions, thus inactivating ERK signal 
transduction (“b”). (C) Bypassing PSMA interference by directly activating FAK-Tyr925 
with extracellular matrix (ECM) rescues activation of FAK-Tyr925 and the GRB2/ERK 
signaling pathway. (D) The absence of PSMA allows stable IGF-1R/RACK1/β1 integrin 
complex formation and activation of the FAK-GRB2-ERK canonical pathway, producing 
less aggressive tumors.
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Fig. 7. PSMA levels in human prostate tumors are significantly associated with an increase in 
Gleason score
(A) GEO data set GSE32571 analyzed 59 PCa and 39 matched benign tissue samples for 
transcriptional differences between tumor samples with higher Gleason score (4 + 3 and 
higher) against samples of lower Gleason score (3 + 4 and lower). High PSMA gene 
expression is concurrent with high Gleason score in human tumor samples. (B and C) 
Abundances of survivin and IGF-1R are high in more aggressive tumors. (D) Abundance of 
caspase-9 (CASP9) decreases with tumor aggressiveness. Subgroup labels are along the 
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bottom of the chart. Benign: n = 39; “3 + 4”: tumors with a low Gleason score, n = 32; “4 
+ 3”: tumors with a high Gleason score, n = 27. Groups that reach **P < 0.005 are indicated 
on the graph. Gene expression on the y axis is presented as the relative expression of the 
gene of interest compared to all the other genes in the array. A distribution analysis of all 
selected samples determined that all selected samples were suitable for comparison. Data 
analysis was completed using GEO2R, for which the R script is provided in data file S1.
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Table 2
Prostate mean distribution–adjusted lesion grades
The mean distribution–adjusted lesion grades for the WT and PSMA KO groups from Table 1 are summarized 
here. Data are means ± SE.
Lobe Age in weeks WT KO
Anterior 8 6.8 ± 0.20 5.7 ± 0.16
18 10.4 ± 0.21 8.1 ± 0.17
30 12.2 ± 0.26 13.3 ± 0.04*
Dorsal 8 8.5 ± 0.16 7.3 ± 0.03*
18 11.7 ± 0.07 10.1 ± 0.05*
30 13.3 ± 0.36 13.6 ± 0.21
Ventral 8 7.3 ± 0.15 6.4 ± 0.07
18 10.7 ± 0.10 9.1 ± 0.03*
30 12.3 ± 0.12 13.4 ± 0.15
*P < 0.05.
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